Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from NovoCure

Novocure Stock Earns 96 RS Rating

Novocure sees its Relative Strength Rating hit the elite 90-plus level.

Investors Business Daily

Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds

Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.

Investors Business Daily

Navigating 5 Analyst Ratings For NovoCure

5 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novocure Gets RS Rating Upgrade

Novocure shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.

Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.

Investors Business Daily

Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish

Novocure stock surged Wednesday after its medtech device nearly doubled the length of time patients with brain tumors lived before worsening.

Investors Business Daily

Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails

Novocure said Monday its cancer treatment failed to make a difference for ovarian cancer patients, and NVCR stock crashed.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review

The stock market rally showed strong gains in small caps, while the Nasdaq held up. Apple unveiled its Vision Pro goggles, while the SEC targeting crypto giants.

Investors Business Daily

Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops +40%

Novocure shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Novocure Crashes 43% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment

A medical device from Novocure extended overall survival for lung cancer patients, but the company's shares crashed on muddy test results.

Investors Business Daily

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Barchart

Novocure Has Fallen More Than 22% Over Seven Days — Why It Fell From Grace

Novocure will win a 10% of its targeted lung cancer market, an analyst predicted Tuesday as he examined NVCR stock's double-digit drop.

Investors Business Daily

Novocure Skyrockets 69% After Pulling Off A Once-In-Six-Years Feat

Adding Novocure's medical device to standard drugs improved survival for late-stage lung cancer patients, leading NVCR stock to soar Thursday.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2022

Upgrades

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Benzinga

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022

Upgrades

Benzinga

Looking Into NovoCure's Return On Capital Employed

According to data from Benzinga Pro, during Q1, NovoCure's (NASDAQ:NVCR) reported sales totaled $137.55 million. Despite a 82.44% increase in earnings, the company posted a loss of $4.65 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

NovoCure: Q1 Earnings Insights

NovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga

Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control

Novocure Ltd (NASDAQ: NVCR)

Benzinga

Where NovoCure Stands With Analysts

NovoCure (NASDAQ:NVCR) has observed the following analyst ratings within the last quarter:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.